Zylox-Tonbridge Medical Technology Co (FRA:818) Total Operating Expense: €65.3 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:818 Zylox-Tonbridge Medical Technology Co Ltd FRA:818
76 GF Score
Price €2.08
GF Value €3.72
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Zylox-Tonbridge Medical Technology Co Total Operating Expense?

Zylox-Tonbridge Medical Technology Co FRA:818 -2.80% 76 Total Operating Expense is €65.3 Mil as of Dec. 2025. GuruFocus rates FRA:818 with a GF Score™ of 76/100 and a GF Value™ of €3.72 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Zylox-Tonbridge Medical Technology Co's Total Operating Expense for the six months ended in Dec. 2025 was €35.9 Mil. Zylox-Tonbridge Medical Technology Co's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €65.3 Mil.

Zylox-Tonbridge Medical Technology Co Total Operating Expense Related Terms

Zylox-Tonbridge Medical Technology Co Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Zylox-Tonbridge Medical Technology Co's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zylox-Tonbridge Medical Technology Co Total Operating Expense Chart

Zylox-Tonbridge Medical Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 48.66 64.30 67.95 63.33 65.47

Zylox-Tonbridge Medical Technology Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.46 27.71 34.94 29.42 35.92
FRA:818
76GF Score
Zylox-Tonbridge Medical Technology Co Ltd FRA:818
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zylox-Tonbridge Medical Technology Co Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €65.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €65.3 Mil mean?
Zylox-Tonbridge Medical Technology Co (FRA:818) has a Total Operating Expense of €65.3 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Zylox-Tonbridge Medical Technology Co and its competitors.
Is Zylox-Tonbridge Medical Technology Co's Total Operating Expense too high?
Zylox-Tonbridge Medical Technology Co's current Total Operating Expense is €65.3 Mil. Overall, Zylox-Tonbridge Medical Technology Co has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zylox-Tonbridge Medical Technology Co's Total Operating Expense compare to ABT and SYK?
Zylox-Tonbridge Medical Technology Co's Total Operating Expense of €65.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Devices & Instruments company?
A good Total Operating Expense depends on the Medical Devices & Instruments industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Zylox-Tonbridge Medical Technology Co and its competitors. Zylox-Tonbridge Medical Technology Co's current Total Operating Expense is €65.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zylox-Tonbridge Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co (FRA:818) is currently considered Significantly Undervalued. The stock's GF Value™ is €3.72, compared to a current price of €2.08 — trading 44.1% below its estimated fair value. The current Total Operating Expense is €65.3 Mil. Zylox-Tonbridge Medical Technology Co's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Zylox-Tonbridge Medical Technology Co (FRA:818), the current Total Operating Expense is €65.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zylox-Tonbridge Medical Technology Co (FRA:818) Overvalued in 2026?

Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co stock appears to be undervalued. The current stock price of €2.08 is trading 44.1% below its estimated GF Value™ of €3.72. GuruFocus considers Zylox-Tonbridge Medical Technology Co to be Significantly Undervalued.

Key valuation signals for FRA:818:

  • Total Operating Expense: €65.3 Mil
  • GF Value™: €3.72 vs. price of €2.08 (44.1% below fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the FRA:818 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zylox-Tonbridge Medical Technology Co Business Description

Other Exchanges 02190:Hong Kong
Address 270 Shuyun Road, Cangqian Street, Zylox-Tonbridge Industrial Park, Yuhang District, Zhejiang Province, Hangzhou, CHN
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's products include Thrombite Clot Retriever Device (Thrombite CRD), Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB), and others. The company derives majority of its revenue from PRC.
76GF Score

Get the complete analysis for FRA:818

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.08
Price
€3.72
GF Value